In November, AstraZeneca announced that the phase 3 MYSTIC trial investigating durvalumab (Imfinzi) monotherapy and durvalumab in combination with tremelimumab in patients with previously untreated stage IV non–small cell lung cancer (NSCLC) did not meet its primary end point.
In November, AstraZeneca announced that the phase 3 MYSTIC trial investigating durvalumab (Imfinzi) monotherapy and durvalumab in combination with tremelimumab in patients with previously untreated stage IV non—small cell lung cancer (NSCLC) did not meet its primary end point.
The MYSTIC trial, a phase 3, randomized, open-label, multicenter, global trial, studied monotherapy or combination durvalumab with tremelimumab versus the standard of care chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type, locally advanced, or metastatic NSCLC.
Primary end points included progression-free survival with the combination and overall survival with the monotherapy and combination treatment. The combination of durvalumab and tremelimumab did not meet the primary end point of improving progression-free survival compared with the current standard of care in patients whose tumors express PD-L1 on 25% or more of their cancer cells.
While the overall survival did not achieve statistical significance, a hazard ratio of 0.76 (97.54% CI, 0.564-1.019; nominal P = .036) was demonstrated with durvalumab as a monotherapy. The combination treatment displayed a hazard ratio of 0.85 (98.77% CI, 0.611-1.173; nominal P = .202). “The data support further analysis in exploratory subgroups,” read the press release.
Additionally, the safety and tolerability of durvalumab and durvalumab plus tremelimumab were consistent with what has been seen in previous trials.
Durvalumab is currently approved for unresectable stage III NSCLC in more than 40 countries, including the US, European Union, and Japan. Phase 3 trials investigating the drug for the treatment of stage IV NSCLC are ongoing.
“We are encouraged to see that Imfinzi monotherapy activity is in-line with that of the anti-PD-1 class in previously-untreated patients with stage IV [NSCLC]; however, we are disappointed that these results missed statistical significance,” said Sean Bohen, executive vice president, global medicines development and chief medical officer at AstraZeneca.
“We remain confident in Imfinzi as the cornerstone of our [immuno-oncology] program and continue to evaluate its potential in ongoing [NSCLC] trials, including Imfinzi and Imfinzi plus tremelimumab in combination with chemotherapy.”
Study Highlights BMP7 As a Potential Therapeutic Target for Ovarian Cancer
November 30th 2023High Bone Morphogenetic Protein 7 (BMP7) expression was significantly associated with aggressive phenotypes, including advanced grade, International Federation of Gynecology and Obstetrics stage, residual disease, and adverse overall survival.
Read More
7-Day Dosing of Azacytidine Shows Benefit for Females With High-Risk MDS Not Seen in Males
November 30th 2023Investigators from several medical centers in Japan were surprised to find that women with myelodysplastic syndrome (MDS) had a survival advantage from a 7-day dosing schedule, but that benefit compared with a reduced schedule was not seen in men.
Read More
Contributor: More Informed Management of Preeclampsia Is Necessary
November 29th 2023At present, it is difficult for clinicians to identify patients at greatest risk for developing preeclampsia with severe features and tailor treatment plans for them; this difficulty increases costs significantly.
Read More